Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Michael Sharpe (Department of Psychiatry) and colleagues identify that treating depression doesn’t make cancer patients live longer, but it does make lives immeasurably better

A follow up study led by Professor Michael Sharpe at the University of Oxford’s Department of Psychiatry – ‘Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials’ – has been published in The Lancet Psychiatry.

It reveals that contrary to the findings of previous small studies, treating depression in cancer patients does not increase the length of life of people with cancer. However the previous publications from these trials found that the benefits to patients’ quality of life are clear and significant.

Find out more (Department of Psychiatry website)

Similar stories

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

Clinical Trials Coronavirus COVID-19 General Research

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).